Zhitong Finance APP learned that before the US stock market on February 11 (Friday), as of press time, Cassava Sciences (SAVA. US) rose 8.01 percent at $57.3. On the news side, the U.S. Food and Drug Administration (FDA) rejected a citizens' petition to suspend a key trial of Cassava Sciences' Alzheimer's drug simufilam.